Media stories about Neovasc (NASDAQ:NVCN) (TSE:NVC) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neovasc earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 47.5716757989424 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- 50 days simple moving average (SMA50) to Track: Neovasc Inc. (NASDAQ:NVCN), Genworth Financial, Inc. (NYSE … (stocksnewspoint.com)
- Swiveling Three Stocks: Neovasc Inc. (NASDAQ:NVCN), TransAtlantic Petroleum Ltd. (NYSE:TAT), Advaxis, Inc … (thestreetpoint.com)
- Is The Stock Ready to Shift Trend? – Neovasc Inc. (NASDAQ: NVCN) (stocktradingdesk.com)
- Stock to Watch – Neovasc Inc. (NVCN) (nasdaqfortune.com)
- Notable Moving Stock: Neovasc Inc. (NVCN) (nasdaqexpress.com)
Several equities research analysts have recently commented on the company. Zacks Investment Research lowered Neovasc from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. ValuEngine raised Neovasc from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Canaccord Genuity reissued a “buy” rating and set a $1.05 price target on shares of Neovasc in a research note on Friday, January 19th. Finally, Leerink Swann decreased their price target on Neovasc from $5.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, March 29th.
Neovasc (NASDAQ:NVCN) (TSE:NVC) last issued its quarterly earnings data on Wednesday, March 28th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.01). Neovasc had a negative return on equity of 85.81% and a negative net margin of 1,687.90%. The company had revenue of $1.23 million for the quarter, compared to analyst estimates of $1.18 million. equities research analysts expect that Neovasc will post -0.09 earnings per share for the current fiscal year.
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.